phenethyl-malonic acid diamide | 51052-71-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenethyl-malonic acid diamide
• 英文别名: Phenaethyl-malonsaeure-diamid；2-(2-Phenylethyl)propanediamide
• CAS: 51052-71-2
• 化学式: C₁₁H₁₄N₂O₂
• 分子量: 206.244
• InChiKey: STEHUTPTKQGTOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-苯基乙基丙二酸二乙酯 在 氨 作用下， 以 甲醇 为溶剂， 以95%的产率得到phenethyl-malonic acid diamide
  参考文献：
  名称：

  Solution Parallel Synthesis of Cyclic Guanidines

  摘要：

  DOI：

  10.3987/com-00-8884

文献信息

• Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
  申请人：Gluckman David Peter

  公开号：US20060251649A1

  公开（公告）日：2006-11-09

  Aspects of this invention include the use of G-2MePE to treat patients with brain injury characterized by non-convulsive seizures. G-2MePE is useful in treating brain injuries caused by traumatic brain injury, stroke, hypoxia/ischemia and toxic injury.

  这项发明的方面包括使用G-2MePE来治疗患有非惊厥性癫痫的脑损伤患者。G-2MePE在治疗因创伤性脑损伤、中风、缺氧/缺血和毒性损伤引起的脑损伤方面很有用。
• Drug adherence monitoring system
  申请人：Dennis Donn Michael

  公开号：US20070224128A1

  公开（公告）日：2007-09-27

  The present invention provides novel methods for monitoring subject adherence in taking prescribed drugs by detecting markers in exhaled breath after a subject takes the prescribed drug. In particular, the present invention provides novel methods for making additives that are combined with the drug(s). Upon biological breakdown of the drug/additive formulation in a subject's body, markers resulting directly from the biological breakdown of the additives are detected in exhaled breath using sensor technology. In certain embodiments of the invention, the drug adherence monitoring systems and methods include a reporting system capable of tracking subject compliance (either remotely or proximately) and of providing necessary alerts to the subject, caregiver, healthcare provider, and the like.

  本发明提供了一种通过检测受试者服用处方药后呼出气中的标记物来监测受试者服药依从性的新方法。特别地，本发明提供了一种制备与药物结合的添加剂的新方法。在受试者体内药物/添加剂配方被生物降解后，使用传感器技术检测直接由添加剂生物降解产生的标记物在呼出气中的存在。在本发明的某些实施例中，药物依从性监测系统和方法包括一个报告系统，能够远程或近距离跟踪受试者的依从性，并向受试者、看护人、医疗保健提供者等提供必要的警报。
• System and method for real-time diagnosis, treatment, and therapeutic drug monitoring
  申请人：University of Florida Research Foundation, Inc.

  公开号：EP1990639A1

  公开（公告）日：2008-11-12

  Systems and methods for diagnosing and/or treating diseases as well as monitoring disease treatment. For diagnosis, the present invention uses nanoparticle-based assemblies, which comprise a nanoparticle; a surrogate marker; and a means for detecting a specific chemical entity. In certain embodiments, nanoparticle-based assemblies include a payload for simultaneous diagnosis and treatment of disease. In further embodiments, a therapeutic drug and therapeutic drug marker are administered to a patient to monitor disease treatment. Bodily fluid samples are analyzed using sensor technology to detect the presence of surrogate and/or therapeutic drug markers to provide an efficient and accurate means for diagnosing a disease and/or monitoring disease treatment.

  诊断和/或治疗疾病以及监测疾病治疗的系统和方法。在诊断方面，本发明使用基于纳米粒子的组件，其中包括纳米粒子、替代标记物和检测特定化学实体的方法。在某些实施方案中，基于纳米粒子的组件包括一个有效载荷，用于同时诊断和治疗疾病。在进一步的实施方案中，向患者施用治疗药物和治疗药物标记物，以监测疾病治疗情况。使用传感器技术对体液样本进行分析，检测代用药物和/或治疗药物标记物的存在，为诊断疾病和/或监测疾病治疗提供高效准确的方法。
• Method of treating movement disorders using barbituric acid derivatives
  申请人：Taro Pharmaceutical Industries Ltd.

  公开号：EP2156839A1

  公开（公告）日：2010-02-24

  The present invention relates to the use of a compound according to the following formula: or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are the same or different and are each independently phenyl or lower alkyl substituted phenyl; and R1 and R2 are each independently either a hydrogen atom or a radical of the formula wherein R5 and R6 are each independently selected from the group consisting of H, lower alkyl, phenyl, and lower alkyl substituted phenyl, for the preparation of a medicament for treating movement disorders.

  本发明涉及下式化合物的用途： 或其药学上可接受的盐，其中 R3 和 R4 相同或不同，且各自独立地为苯基或低级烷基取代的苯基；R1 和 R2 各自独立地为氢原子或式中的基团 其中 R5 和 R6 各自独立地选自由 H、低级烷基、苯基和低级烷基取代的苯基组成的组，用于制备治疗运动障碍的药物。
• PRIMIDONE IN THE USE FOR INHIBITING CELL DEATH IN DISEASES LIKE REPERFUSION INJURY DISEASE, NEURODEGENERATIVE DISEASE ETC
  申请人：Christian-Albrechts-Universität zu Kiel

  公开号：EP3789028A1

  公开（公告）日：2021-03-10

  The present invention relates to the field of diseases or conditions that involve a pathologic level of RIPK1-dependent cell death. Specifically, the present invention refers to the use of the compound primidone or a pharmaceutically acceptable active metabolite, derivative, salt or solvate thereof for treating a disease or condition that involves a pathologic degree of RIPK1-dependent cell death. In a further aspect, the present invention provides a pharmaceutical composition comprising primidone or a pharmaceutically acceptable active metabolite, derivative, salt or solvate thereof for treating a disease or condition that involves a pathologic degree of RIPK1-dependent cell death.

  本发明涉及涉及病理水平的 RIPK1 依赖性细胞死亡的疾病或病症领域。具体地说，本发明指的是化合物骁悉或其药学上可接受的活性代谢物、衍生物、盐或溶液剂用于治疗涉及病理程度的 RIPK1 依赖性细胞死亡的疾病或病症的用途。在另一个方面，本发明提供了一种药物组合物，该组合物包含骁悉或其药学上可接受的活性代谢物、衍生物、盐或溶解物，用于治疗涉及病理程度的 RIPK1 依赖性细胞死亡的疾病或病症。